Double PPAR agonists for non-alcoholic fatty hepatitis: Phase III clinical failure.
-
Last Update: 2020-07-30
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
!---- Genfit announced the termination of the Phase III trial for elafibranor treatment for patients with fibrosis non-alcoholic fatty hepatitis (NASH).this move was based on an interim analysis of the phase III RESOLVE-IT trial data, which showed that the dual PPAR agonisant failed to reach the primary therapeutic end point: mitigation of NASH and no deterioration of fibrosis.image source: After a detailed review of the data, the company decided to abandon the data, arguing that the available data were not sufficient to support elafibranor's marketing applications in the United States and Europe.Genfit said the decision was an important step in the company's strategy to save costs and focus on elastic fibrosis of primary bile ductitis (PBC) and the commercial development of NIS4 for NASH diagnostics..
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
